GLP1R and Alzheimer disease: In the aforementioned context, GLP-1 analogs were shown to inhibit the Tau pathology-associated activities of p38 in the hippocampus of APP/PS1 mice (Cai et al., 2018) and JNK in multiple Aβ-induced AD animal models (Bomfim et al., 2012; Chen S. et al., 2017).